<DOC>
	<DOCNO>NCT00322452</DOCNO>
	<brief_summary>The purpose study compare gefitinib carboplatin / paclitaxel doublet chemotherapy give first line treatment term progression free survival select NSCLC patient objective demonstrate non-inferiority .</brief_summary>
	<brief_title>First Line IRESSAâ„¢ Versus Carboplatin/Paclitaxel Asia</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Locally advanced Stage IIIB amenable local therapy Stage IV ( metastatic ) NSCLC adenocarcinoma histology . Never smoker light exsmokers . ( ceased smoking least 15 year Day 1 study treatment 10 packyears few ) Had prior chemotherapy , biological ( include target therapy EGFR vascular epidermal growth factor ( VEGF ) inhibitor ) immunological therapy . Preexisting idiopathic pulmonary fibrosis evidence CT scan baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Gefitinib</keyword>
</DOC>